Braftovi, Erbitux, and Mektovi: Evaluating the Global Market Landscape and Trends till 2032
Overview of Braftovi + Erbitux ± Mektovi Combination Therapy The combination of Braftovi (encorafenib), Erbitux (cetuximab), and optionally Mektovi (binimetinib) has become a pivotal treatment approach for certain cancers, particularly metastatic colorectal cancer (mCRC) with the BRAFV600E mutation. This targeted therapy works by inhibiting the